| Previous Close | 8.66 |
| Open | 9.19 |
| Bid | 7.30 x 800 |
| Ask | 10.95 x 800 |
| Day's Range | 8.66 - 9.23 |
| 52 Week Range | 7.18 - 9.60 |
| Volume | 29,449 |
| Avg. Volume | 200,078 |
| Market Cap | 160.302M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -58.45 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Trevi Therapeutics, Inc. (“Trevi”), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced the pricing of its initial public offering of 5,500,000 shares of its common stock at an initial public offering price of $10.00 per share, for gross proceeds of $55 million. In addition, Trevi has granted the underwriters a 30-day option to purchase up to an additional 825,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. All of the shares are being offered by Trevi.
Trevi Therapeutics, Inc. will issue nearly 4.7 million shares on the Nasdaq under ticker TRVI, according to the firm’s S-1 filing. Lead underwriters include SVB Leerink, Stifel and BMO Capital Markets. The Connecticut biotech targets chronic pruritis, chronic cough related to idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia related to Parkinson’s disease.